Federated Hermes
VIRX

Federated Hermes’s Viracta Therapeutics, Inc. Common Stock VIRX Stock Holding History

Federated Hermes’s Portfolio VIRX Stock Details VIRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q4 		– Sell
-238
Closed -$357K – 2060
2014
Q3 		$357K Buy
+238
New +$345K ﹤0.01% 1434

Other funds holding VIRX

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
MCM
MAI Capital Management Independence, Ohio $17.7B AUM 18.87% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Federated Hermes's VIRX Position: Q1 2022 in Review

Federated Hermes sold out of Viracta Therapeutics, Inc. Common Stock (VIRX) in Q1 2022, closing a stake of 28,582 shares — an estimated $104K sold.

Federated Hermes first reported a position in VIRX in Q1 2014 and held it in 15 quarters. The position peaked at $3.14M in Q1 2014. 69 funds tracked by Wall St. Rank hold VIRX as of Q1 2022.

  • Federated Hermes reported no remaining Viracta Therapeutics, Inc. Common Stock position as of Q1 2022 after selling out during the quarter.
  • Federated Hermes sold 28,582 Viracta Therapeutics, Inc. Common Stock shares in Q1 2022, an estimated $104K.
  • Federated Hermes first reported a position in Viracta Therapeutics, Inc. Common Stock in Q1 2014 and held it in 15 quarters.
  • Federated Hermes's Viracta Therapeutics, Inc. Common Stock position peaked at $3.14M in Q1 2014.
  • 69 funds tracked by Wall St. Rank held Viracta Therapeutics, Inc. Common Stock as of Q1 2022.

Based on Federated Hermes's 13F filing for Q1 2022, filed 13 May 2022.